Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: povidone; titanium dioxide; maize starch; croscarmellose sodium; sodium stearylfumarate; gelatin; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 4 mg - capsule - excipient ingredients: lactose monohydrate; sodium stearylfumarate; maize starch; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 2 mg - capsule - excipient ingredients: lactose monohydrate; povidone; sodium stearylfumarate; maize starch; titanium dioxide; purified water; iron oxide yellow; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 1 mg - capsule - excipient ingredients: maize starch; sodium stearylfumarate; povidone; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: povidone; sodium stearylfumarate; maize starch; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 20 mg; hydrochlorothiazide, quantity: 6 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium bicarbonate; maize starch; lactose monohydrate; purified talc - mild to moderate hypertension. treatment should not be initiated with this fixed dose combination.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - enalapril maleate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - enalapril maleate - oral tablet - 20mg

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - trandolapril 4 mg - trandolapril tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema, and in patients with a history of angioedema related to previous treatment with an ace inhibitor.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - trandolapril 1 mg - trandolapril tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. trandolapril tablets are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of trandolapril to caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see clinical pharmacology -heart failure or left-ventricular dysfunction post myocardial infarction for details of the survival trial). trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ace i